Financial Comparison: Evommune (EVMN) and Its Rivals

Evommune (NYSE:EVMN – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Evommune to similar companies based on the strength of its risk, profitability, institutional ownership, valuation, analyst recommendations, earnings and dividends.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Evommune and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evommune 1 4 10 1 2.69
Evommune Competitors 9945 15356 45765 1601 2.54

Evommune currently has a consensus target price of $30.50, suggesting a potential upside of 333.24%. As a group, “Biotechnology” companies have a potential upside of 114.59%. Given Evommune’s stronger consensus rating and higher probable upside, equities analysts clearly believe Evommune is more favorable than its rivals.

Earnings and Valuation

This table compares Evommune and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Evommune $13.00 million -$68.87 million -1.85
Evommune Competitors $688.58 million $7.69 million -17.98

Evommune’s rivals have higher revenue and earnings than Evommune. Evommune is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Evommune and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Evommune N/A -43.53% -40.11%
Evommune Competitors -12,224.75% -204.85% -31.52%

Institutional and Insider Ownership

47.8% of shares of all “Biotechnology” companies are held by institutional investors. 31.1% of Evommune shares are held by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Evommune beats its rivals on 6 of the 11 factors compared.

About Evommune

(Get Free Report)

Evommune is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases. Founded in 2020, the company focuses on biological pathways involved in inflammation and aims to develop treatments for conditions with significant unmet medical needs. Its pipeline includes EVO756, an oral investigational medicine designed to block MRGPRX2, a receptor involved in mast-cell activation. The candidate is being studied for inflammatory skin disorders, including chronic spontaneous urticaria and atopic dermatitis.

Receive News & Ratings for Evommune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evommune and related companies with MarketBeat.com's FREE daily email newsletter.